What we develop: IP-first deeptech

Ethivolve develops an intellectual property-protected system architecture, established through patent applications and confidential registrations, for context- and phase-aware digital support in human-critical digital systems.

This architecture is aimed at:

  • preventing AI and data harm
  • limiting automation where risk arises
  • strengthening human control and responsibility

The technical, methodological, and implementation details of this intellectual property are not publicly shared.

Underlying proof-of-concept software, verification packages, test suites, lexicons, parameters, hashes, reports and technical artefacts are managed confidentially and shared only under appropriate confidentiality arrangements.

Ethivolve is IP-first: intellectual property forms the core of the enterprise and the basis for future collaboration, licensing, and controlled application.

PGI and EDIM are two concrete examples within a broader portfolio of proprietary system elaborations, methodologies and technical proof-of-concepts by Ethivolve.

PGI: Patient-Generated Information

PGI structures free-form patient language for professional review. It can organise indications relating to potential care needs, experiences of illness and recovery, and the potential influence of social media, online information and patient stories. The structuring is explainable and traceable to the original text. In this way, PGI aligns with European attention to digital systemic risks relating to VLOPs and VLOSEs under the Digital Services Act. PGI does not monitor platforms and does not provide diagnosis, triage or treatment advice.

Proof of concept (TRL 3); not clinically validated.

EDIM: Ethical Digital Interpretation Methodology

EDIM is an experimental, non-clinical methodology focused on the traceability and reproducibility of information interpretation in regulatory science contexts.

In exploratory correspondence, the European Medicines Agency (EMA) recognised the innovative aspects of the development and its potential relevance for regulatory science research. This does not constitute EMA validation, qualification or approval.

Licensing and cooperation

The intellectual property forms the basis for licensing, co-development, and controlled market application in regulated domains.

Each party retains its own intellectual property. Cooperation always starts with delimitation, not with implementation. Cooperation does not imply transfer or disclosure of intellectual property.